Challenges and recommendations for early identification of metastatic disease in prostate cancer

Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8.

Abstract

Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.

Publication types

  • Consensus Development Conference
  • Review

MeSH terms

  • Bone Neoplasms / blood
  • Bone Neoplasms / diagnosis*
  • Bone Neoplasms / secondary
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Multimodal Imaging
  • Patient Selection
  • Positron-Emission Tomography
  • Practice Guidelines as Topic
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / pathology*
  • Soft Tissue Neoplasms / blood
  • Soft Tissue Neoplasms / diagnosis*
  • Soft Tissue Neoplasms / secondary
  • Tomography, X-Ray Computed

Substances

  • Prostate-Specific Antigen